Table 2 | IPTi coverage in study areas
Only one dose | Only two doses | Three doses | |
|---|---|---|---|
A. Doses received, irrespective of EPI timepoint* | |||
Received (n/N) | 73/707 | 197/707 | 368/707 |
Weighted Proportion (95% CI) | 10.42% (7.88–13.65) | 27.97% (23.84–32.50) | 50.57% (45.38–55.75) |
One or more doses | Two or more doses | Three doses | |
|---|---|---|---|
B. Cumulative doses received, irrespective of EPI timepoint | |||
Received (n/N) | 638/707 | 565/707 | 368/707 |
Weighted Proportion (95% CI) | 88.96% (85.54–91.65) | 78.54% (74.30–82.25) | 50.57% (45.38–55.75) |
IPTi1 (10 weeks) | IPTi2 (14 weeks) | IPTi3 (9 months) | |
|---|---|---|---|
C. Doses received at each EPI contact | |||
Received (n/N) | 574/707 | 577/707 | 420/707 |
Weighted Proportion (95% CI) | 80.26% (75.30–84.44) | 80.09% (76.30–83.40) | 57.72% (53.20–62.11) |